October 21, 2024
SAVANNAH, GEORGIA — Current disease-modifying therapies for amyotrophic lateral sclerosis (ALS) don’t extend lifespans by much, but several drug options are available, nerve specialists learned. The […]
October 21, 2024
The American Stroke Association (ASA) has issued an updated guideline for primary stroke prevention. The first update in a decade, the 2024 Guideline for the Primary […]
October 21, 2024
SAVANNAH, Georgia — Heart problems are common in the vast majority of neuromuscular disorders, and cardiac monitoring of patients is crucial, even at younger ages, a […]
October 18, 2024
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, […]
October 18, 2024
The European Medicines Agency (EMA) has upheld an earlier recommendation to deny marketing authorization for Masitinib AB Science (masitinib), an oral treatment for amyotrophic lateral sclerosis […]
October 18, 2024
SAVANNAH, GEORGIA — One patient with autoimmune myasthenia gravis (MG) has a niece with the same diagnosis, and at least one of his other close relatives […]
October 18, 2024
The American Heart Association (AHA) has issued a new scientific statement on the link between heart failure (HF), atrial fibrillation (AF), and coronary heart disease (CHD) […]
October 18, 2024
TOPLINE: Galcanezumab was associated with significantly less dizziness in patients with vestibular migraine (VM) compared with placebo, suggests new results from the first randomized clinical trial […]
October 17, 2024
The US Food and Drug Administration (FDA) has approved Avadel Pharmaceuticals’ supplemental new drug application for extended-release sodium oxybate (Lumryz) for treatment of cataplexy or excessive […]